Friday, March 14, 2025 6:33:05 AM
The dude is a well known know it all pumper, yet does not expect shareholders to be making money on their NWBO investment! ;)
Either way, none of this matters. The revenue from the UK will be so tiny in 2025 and 2026. Less than $15M annually (without reimbursement support). More importantly, it’s clear there will be no non dilutive funds from big pharma. Which means endless dilution in 2025 & 2026. Another thing that is quite likely is a lawsuit in Q4, 2025. Lies and dangling of carrots catches up at around the 5 year anniversary of data lock.
UK approval may present the best opportunity to take whatever money off the table one can over the next couple of years while LP continues to dilute shareholders to oblivion. Watch out for the next set of carrots - Flaskworks, fast combo trial(s), etc. Unfortunately, they don't have money to do any of this aggressively and in a reasonable time frame. Yet expect dilution to increase massively. LP will beg shareholders to raise authorized share count at the ASM this year. Wait and watch!
Either way, none of this matters. The revenue from the UK will be so tiny in 2025 and 2026. Less than $15M annually (without reimbursement support). More importantly, it’s clear there will be no non dilutive funds from big pharma. Which means endless dilution in 2025 & 2026. Another thing that is quite likely is a lawsuit in Q4, 2025. Lies and dangling of carrots catches up at around the 5 year anniversary of data lock.
UK approval may present the best opportunity to take whatever money off the table one can over the next couple of years while LP continues to dilute shareholders to oblivion. Watch out for the next set of carrots - Flaskworks, fast combo trial(s), etc. Unfortunately, they don't have money to do any of this aggressively and in a reasonable time frame. Yet expect dilution to increase massively. LP will beg shareholders to raise authorized share count at the ASM this year. Wait and watch!
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
